NMN
About
About NMN
Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+ and is rapidly absorbed and converted to NAD+ in tissues. It has gained significant attention from longevity researchers including David Sinclair for its potential to reverse aspects of cellular aging. Animal studies show improvements in energy metabolism, mitochondrial function, and lifespan. Human trials are ongoing with encouraging preliminary data.
Science
Mechanism of Action
Converted to NAD+ via the Preiss-Handler pathway, NMN replenishes the NAD+ pool that declines with age, restoring sirtuin activity, mitochondrial function, and DNA repair capacity.
Dosing
Typical Protocol
250–1,000 mg oral once daily in the morning; sublingual and liposomal forms may improve bioavailability.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer NMN — with trust scores, legal credentials, and pricing transparency.